SC 13G

Name of Reporting Persons:

Clarus Lifesciences III, L.P.

Check the Appropriate Box if a Member of a Group

(a) ☐ (b) ☒

SEC Use Only

Citizenship or Place of Organization:

Delaware

SC 13G 1 d103248dsc13g.htm SC 13G SC 13G

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934

(Amendment No. )*

Graybug Vision, Inc.

(Name of Issuer)

Common Stock, par value $0.0001 per share

(Title of Class of Securities)

38942Q103

(CUSIP Number)

December 31, 2020

(Date of Event which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

☐ Rule 13d-1(b)

☐ Rule 13d-1(c)

☒ Rule 13d-1(d)

*	The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).


CUSIP No. 38942Q103		13G		Page 2 of 17


CUSIP No. 38942Q103		13G		Page 3 of 17


CUSIP No. 38942Q103		13G		Page 4 of 17


CUSIP No. 38942Q103		13G		Page 5 of 17


CUSIP No. 38942Q103		13G		Page 6 of 17


CUSIP No. 38942Q103		13G		Page 7 of 17


CUSIP No. 38942Q103		13G		Page 8 of 17


CUSIP No. 38942Q103		13G		Page 9 of 17

Item 1.

(a).

Name of Issuer

Graybug Vision, Inc. (the “Issuer”)

(b).

Address of Issuer’s Principal Executive Offices:

275 Shoreline Drive, Suite 450

Redwood City, CA 94065

Item 2(a).

Name of Person Filing

Item 2(b).

Address of Principal Business Office

Item 2(c).

Citizenship

Each of the following is hereinafter individually referred to as a “Reporting Person” and collectively as the “Reporting Persons.” This statement is filed on behalf of:

(i)

Clarus Lifesciences III, L.P.

c/o Clarus Ventures

101 Main Street, Suite 1210

Cambridge, MA 02142

SEC Form SC 13G filed